Global Alpha Capital Management Ltd. Has $32.01 Million Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Global Alpha Capital Management Ltd. raised its holdings in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 1.8% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 536,450 shares of the specialty pharmaceutical company’s stock after acquiring an additional 9,500 shares during the period. ANI Pharmaceuticals makes up 2.1% of Global Alpha Capital Management Ltd.’s holdings, making the stock its 23rd largest position. Global Alpha Capital Management Ltd. owned 2.55% of ANI Pharmaceuticals worth $32,005,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Vanguard Group Inc. raised its position in shares of ANI Pharmaceuticals by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 1,306,432 shares of the specialty pharmaceutical company’s stock valued at $90,314,000 after acquiring an additional 17,460 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of ANI Pharmaceuticals by 3.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 630,226 shares of the specialty pharmaceutical company’s stock valued at $40,132,000 after buying an additional 21,053 shares in the last quarter. Millennium Management LLC increased its position in shares of ANI Pharmaceuticals by 1,005.8% in the 2nd quarter. Millennium Management LLC now owns 230,079 shares of the specialty pharmaceutical company’s stock valued at $14,651,000 after buying an additional 209,272 shares in the last quarter. Thompson Siegel & Walmsley LLC increased its position in shares of ANI Pharmaceuticals by 1.5% in the 2nd quarter. Thompson Siegel & Walmsley LLC now owns 195,743 shares of the specialty pharmaceutical company’s stock valued at $12,465,000 after buying an additional 2,986 shares in the last quarter. Finally, Mizuho Markets Americas LLC bought a new stake in shares of ANI Pharmaceuticals in the 3rd quarter valued at $11,670,000. Institutional investors own 76.05% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on ANIP. HC Wainwright restated a “buy” rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a research report on Monday, November 11th. Raymond James upped their price objective on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a research report on Wednesday, September 18th. StockNews.com cut ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, September 7th. Truist Financial increased their target price on ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a report on Tuesday, October 22nd. Finally, Piper Sandler assumed coverage on ANI Pharmaceuticals in a report on Friday, October 11th. They set an “overweight” rating and a $68.00 target price for the company. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $77.33.

ANI Pharmaceuticals Trading Up 0.8 %

ANI Pharmaceuticals stock opened at $55.69 on Wednesday. The firm has a 50-day moving average of $58.34 and a 200-day moving average of $61.11. ANI Pharmaceuticals, Inc. has a one year low of $48.20 and a one year high of $70.81. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. The company has a market cap of $1.17 billion, a price-to-earnings ratio of -101.25 and a beta of 0.71.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings data on Friday, November 8th. The specialty pharmaceutical company reported $1.34 EPS for the quarter, topping analysts’ consensus estimates of $1.09 by $0.25. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The company had revenue of $148.30 million during the quarter, compared to the consensus estimate of $144.37 million. During the same period in the prior year, the business posted $1.05 EPS. The company’s quarterly revenue was up 12.5% on a year-over-year basis. On average, equities analysts expect that ANI Pharmaceuticals, Inc. will post 3.5 earnings per share for the current fiscal year.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.